Eli Lilly Stock Soars with GLP-1 Zepbound for Sleep Apnea
LLY Eli Lilly and Company $918.00 +3.43 (+0.38%) (As of 07/8/2024 ET) 52-Week Range $434.34 ▼ $928.60 Dividend Yield 0.57% P/E Ratio 135.20 Price Target $816.78 Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but…